Central nervous system acting drugs in treatment of migraine headache

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 158-172

  Samsam, Mohtashem ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

CNS acting drugs; Migraine treatment; Trigeminal nucleus

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANTIMIGRAINE AGENT; BISOPROLOL; BOTULINUM TOXIN A; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CENTRAL NERVOUS SYSTEM AGENTS; ELETRIPTAN; FLUNARIZINE; GABAPENTIN; MECLOFENAMIC ACID; METHYSERGIDE; METOPROLOL; NAPROXEN; NEUROTRANSMITTER; OPIATE; PETHIDINE; PROPRANOLOL; RIZATRIPTAN; SODIUM CHANNEL NAV1.1; SUMATRIPTAN; TIZANIDINE; TONABERSAT; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

ACUPUNCTURE; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; BRAIN STEM; CALCIUM TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG ABUSE; FAMILIAL HEMIPLEGIC MIGRAINE; GENE MUTATION; GENETIC ASSOCIATION; HEADACHE; HOMEOSTASIS; HUMAN; MIDDLE CEREBRAL ARTERY; MIGRAINE; MIGRAINE AURA; MIGRAINE WITH AURA; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; PETASITES; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TRIGEMINAL NERVE; VASOCONSTRICTION;

ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; MIGRAINE DISORDERS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 84866722645     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412802430147     Document Type: Article

References (221)

1. Goadsby, P.J. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol. Med., 2007, 13, 39-44.
2. Goadsby, P.J. The vascular theory of migraine--a great story wrecked by the facts. Brain, 2009, 132, 6-7.
3. Olsen, J. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia, 2004, 241, 9-160.
4. Breslau, N.; Rasmussen, B.K. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology, 2001, 56, S4-12.
5. Rasmussen, B.K.; Olesen, J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia, 1992, 12, 221-228.
6. Gérardy, P.Y.; Fumal, A.; Schoenen, J. Epidemiology and economic repercussion of headache: an inquiery among the administrative and technical personnel of the Liège University. Rev. Med. Liege, 2008, 63, 310-314.
7. Blau, J.N. Migraine prodromes separated from the aura: complete migraine. Br. Med. J., 1980, 281, 658-660.
8. Linde, M. Migraine: a review and future directions for treatment. Acta Neurol. Scand., 2006, 114, 71-83.
9. Lance, J.W.; Lambert, G.A.; Goadsby, P.J.; Duckworth, J.W. Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache, 1983, 23, 258-265.
10. Goadsby, P.J.; Zagami, A.S.; Lambert, G.A. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache, 1991, 31, 365-371.
11. Sprenger, T.; Goadsby, P.J. Migraine pathogenesis and state of pharmacological treatment options. BMC Med., 2009, 16, 7-71.
12. Moskowitz, M.A. The neurobiology of vascular head pain. Ann. Neurol., 1984, 16, 157-168.
13. Haut, S.R.; Bigal, M.E.; Lipton, R.B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol., 2006, 5, 148-57.
14. Bolay, H.; Reuter, U.; Dunn, A.K.; Huang, Z.; Boas, D.A.; Moskowitz, M.A. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med., 2002, 8, 136-42.
15. Goadsby, P.J.; Lipton, R.B.; Ferrari, M.D. Migraine--current understanding and treatment. N. Engl. J. Med., 2002, 346, 257-270.
16. Weiller, C.; May, A.; Limmroth, V.; Juptner, M.; Kaube, H.; Schayck, R.V.; Coenen, H.H.; Diener, H.C. Brain stem activation in spontaneous human migraine attacks. Nat. Med., 1995, 1, 658-660.
17. Spierings, E.L.H. Pathogenesis of the migraine attack. Clin. J. Pain, 2003, 19, 255-262.
18. Denuelle, M.; Fabre, N.; Payoux, P.; Chollet, F.; Geraud, G. Hypothalamic activation in spontaneous migraine attacks. Headache, 2007, 47, 1418-1426.
19. Bahra, A.; Matharu, M.S.; Buchel, C.; Frackowiak, R.S.; Goadsby, P.J. Brainstem activation specific to migraine headache. Lancet, 2001, 357, 1016-1017.
20. Matharu, M.S.; Bartsch, T.; Ward, N.; Frackwiak, R.S.; Weiner, R.; Goadsby, P.J. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain, 2004, 127, 220-230.
21. Afridi, S.K.; Giffin, N.J.; Kaube, H.; Friston, K.J.; Ward, N.S.; Frackowiak, R.S.; Goadsby, P.J. A positron emission tomographic study in spontaneous migraine. Arch. Neurol., 2005, 62, 1270-1275.
22. Cohen, A.S.; Goadsby, P.J. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother., 2006, 6, 1159-1171.
23. Géraud, G.; Denuelle, M.; Fabre, N.; Payoux, P.; Chollet, F. Positron emission tomographic studies of migraine. Rev. Neurol. Paris, 2005, 161, 666-670.
24. th ed.; McGraw Hill: New York, 2000; pp. 473-491.
25. Knight, Y.E.; Goadsby, P.J. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience, 2001, 106, 793-800.
26. Knight, Y.E.; Classey, J.D.; Lasalandra, M.P.; Akerman, S.; Kowacs, F.; Hoskin, K.L.; Goadsby, P.J. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res., 2005, 1045, 1-11.
27. Welch, K.M., Nagesh, V.; Aurora, S.K.; Gelman, N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache, 2001, 41, 629-637.
28. D'Andrea, G.; Leon, A. Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond. Neurol. Sci., 2010, 31 Suppl 1:S1-7.
29. Lauritzen, M.; Olsen, T.; Lassen, N.; Paulson, O. Regulation of regional cerebral blood flow during and between migraine attacks. Ann. Neurol., 1983, 14, 569-572.
30. Lauritzen, M. Cortical spreading depression in migraine. Cephalalgia, 2001, 21, 757-760.
31. Gorji, A. Spreading depression: a review of the clinical relevance. Brain Res. Brain Res. Rev., 2001, 38, 33-60.
32. Sánchez-del-Rio, M.; Reuter, U. Migraine aura: new information on underlying mechanisms. Curr. Opin. Neurol., 2004, 17, 289-293.
33. Tfelt-Hansen, P.; Ashina, M.; Olesen, J. Clinical symptoms and pathophysiology of migraine. Ugeskr. Laeger., 2008, 170, 3231-3234.
34. Goadsby, P.J. Migraine aura: a knockin mouse with a knockout message. Neuron, 2004, 41, 679-780.
35. Goadsby, P.J.; Kullmann, D.M. Another migraine gene. Lancet, 2005, 366, 345-6.
36. Ophoff, R.A.; Terwindt, G.M.; Vergouwe, M.N.; van Eijk, R.; Oefner, P.J.; Hoffman, S.M.; Lamerdin, J.E.; Mohrenweiser, H.W.; Bulman, D.E.; Ferrari, M.; Haan, J.; Lindhout, D.; van Ommen, G.J.; Hofker, M.H.; Ferrari, M.D.; Frants, R.R. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell, 1996, 87, 543-552.
37. Ophoff, R.A.; Van den Maagdenberg, A.M.; Roon, K.I.; Ferrari, M.D.; Frants, R.R. The impact of pharmacogenetics for migraine. Eur. J. Pharmacol., 2001, 413, 1-10.
38. De Fusco, M.; Marconi, R.; Silvestri, L.; Atorino, L.; Rampoldi, L.; Morgante, L.; Ballabio, A.; Aridon, P.; Casari, G. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet., 2003, 33, 192-196.
39. Vanmolkot, K.R.; Kors, E.E.; Hottenga, J.J.; Terwindt, G.M.; Haan, J.; Hoefnagels, W.A.; Black, D.F.; Sandkuijl, L.A.; Frants, R.R.; Ferrari, M.D.; van den Maagdenberg, A.M. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann. Neurol., 2003, 54, 360-366.
40. Dichgans, M.; Freilinger, T.; Eckstein, G.; Babini, E.; Lorenz-Depiereux, B.; Biskup, S.; Ferrari, M.D.; Herzog, J.; van den Maagdenberg, A.M.; Pusch, M.; Strom, T.M. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet, 2005, 366, 371-377.
41. Kors, E.E.; Vanmolkot, K.R.; Haan, J.; Frants, R.R.; van den Maagdenberg, A.M.; Ferrari, M.D. Recent findings in headache genetics. Curr. Opin. Neurol., 2004, 17, 283-288.
42. Wessman, M.; Kaunisto, M.A.; Kallela, M.; Palotie, A. The molecular genetics of migraine. Ann. Med., 2004, 36, 462-473.
43. van den Maagdenberg, A.M.; Pietrobon, D.; Pizzorusso, T.; Kaja, S.; Broos, L.A.; Cesetti, T.; van de Ven, R.C.; Tottene, A.; van der Kaa, J.; Plomp, J.J.; Frants, R.R.; Ferrari, M.D. A Cacna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron, 2004, 41, 701-710.
44. Pietrobon, D. Biological science of headache channels. Handb. Clin. Neurol., 2010, 97,73-83.
45. Hauge, A.W.; Asghar, M.S.; Schytz, H.W.; Christensen, K.; Olesen, J. Effects of tonabersat on migraine with aura: a randomized, double-blind, placebo-controlled crossover study. Lancet Neurol., 2009, 8, 718-23.
46. Ayata, C.; Jin, H.; Kudo, C.; Dalkara, T.; Moskowitz, M.A. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol., 2006, 59, 652-61.
47. Wolthausen, J.; Sternberg, S.; Gerloff, C.; May, A. Are cortical spreading depression and headache in migraine causally linked? Cephalalgia, 2009, 29, 244-9.
48. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC, 2010, 3, 170-188.
49. Tajti, J.; Vécsei, L. The mechanism of peripheral and central sensitization in migraine. A literature review. Neuropsychopharmacol. Hung., 2009, 11, 15-21.
50. Olesen, J.; Bonica, J.J. In: The Management of Pain; Bonica, J.J. Ed.; Lea & Febiger: Philadelphia, 1990, Vol. 1, pp. 687-726.
51. Kruuse, C.; Thomsen, L.; Birk, S.; Oleesen, J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003, 126, 241-247.
52. Burstein, R.; Yarnitsky, D.; Goor-Aryeh, I.; Ransil, B.J.; Bajwa, Z.H. An association between migraine and cutaneous allodynia. Ann. Neurol., 2000, 47, 614-624.
53. Villalón, C.M.; Centurión, D.; Valdivia, L.F.; de Vries, P.; Saxena, P.R. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West Pharmacol. Soc., 2002, 45, 199-210.
54. Silberstein, S.D. Migraine pathophysiology and its clinical implications. Cephalalgia, 2004, 2, 2-7.
55. Asghar, M.S.; Hansen, A.E.; Kapijimpanga, T.; van der Geest, R.J.; van der Koning, P.; Larsson, H.B.; Olesen, J.; Ashina, M. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology, 2010, 75, 1520-6.
56. Limmroth, V.; May, A.; Auerbach, P.; Wosnitza, G.; Eppe, T.; Diener, H.C. Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J. Neurol. Sci., 1996, 138, 60-5.
57. Whyte, C.A.; Tepper, S.J. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev. Neurother., 2009, 9, 1379-91.
58. Evers, S.; Afra, J.; Frese, A.; Goadsby, P.J.; Linde, M.; May, A.; Sándor, P.S. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur. J. Neurol., 2006, 13, 560-572.
59. Evers, S.; Afra, J.; Frese, A.; Goadsby, P.J.; Linde, M.; May, A.; Sándor, P.S. EFNS guideline on the drug treatment of migraine revised report of an EFNS task force. Eur. J. Neurol., 2009, 16, 968-981.
60. Lovell, B.V.; Marmura, M.J. New therapeutic developments in chronic migraine. Curr. Opin. Neurol., 2010, 23, 254-8.
61. Casucci, G.; Villani, V.; Frediani, F. Central mechanism of action of antimigraine prophylactic drugs. Neurol. Sci., 2008, 29, Suppl 1:S123-6.
62. Ramadan, N.M. Current trends in migraine prophylaxis. Headache, 2007, 47, Suppl 1:S52-7.
63. rd edition; Lippincott Williams & Wilkins; Baltimore, 2006; pp. 520-523.
64. McBean, D.E.; Sharkey, J.; Ritchie, I.M.; Kelly, P.A. Evidence for a possible role for serotonergic systems in the control of cerebral blood flow. Brain Res., 1990, 537, 307-310.
65. Edvinsson, L.; Degueurce, A.; Duverger, D.; MacKenzie, E.T.; Scatton, B. Central serotonergic nerves project to the pial vessels of the brain. Nature, 1983, 306, 55-57.
66. Humphrey, P.P.; Feniuk, W.; Marriott, A.S.; Tanner, R.J.; Jackson, M.R.; Tucker, M.L. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol., 1991, 31, 282-90.
67. Ramadan, N.M.; Skljarevski, V.; Phebus, L.A.; Johnson, K.W. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia., 2003, 23, 776-85.
68. Villalón, C.M.; Olesen, J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther., 2009, 124, 309-23.
69. Humphrey, P.P. The discovery and development of the triptans, a major therapeutic breakthrough. Headache., 2008, 48, 685-7.
70. Bigal, M.E.; Krymchantowski, A.V.; Ho, T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq. Neuropsiquiatr., 2009, 67, 559-69.
71. Houghton, L.A.; Fowler, P.; Keene, O.N.; Read, N.W. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment. Pharmacol. Ther., 1992, 6, 685-691.
72. Cipolla, G.; Sacco, S.; Crema, F.; Moro, E.; De Ponti, F.; Frigo, G. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol. Res., 2001, 43, 205-210.
73. Goldstein, D.J.; Roon, K.I.; Offen, W.W.; Ramadan, N.M.; Phebus, L.A.; Johnson, K.W.; Schaus, J.M.; Ferrari, M.D. Selective seratonin 1F (5-HT(1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet, 2001, 358, 1230-4.
74. Lucaites, V.L.; Krushinski, J.H.; Schaus, J.M.; Audia, J.E.; Nelson, D.L. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch. Pharmacol., 2005, 371, 178-84.
75. Filla, S.A.; Mathes, B.M.; Johnson, K.W.; Phebus, L.A.; Cohen, M.L.; Nelson, D.L.; Zgombick, J.M.; Erickson, J.A.; Schenck, K.W.; Wainscott, D.B.; Branchek, T.A.; Schaus, J.M. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides. J. Med. Chem., 2003, 46, 3060-71.
76. Wainscott, D.B.; Krushinski, J.H. Jr.; Audia, J.E.; Schaus, J.M.; Zgombick, J.M.; Lucaites, V.L.; Nelson, D.L. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol., 2005, 37, 169-77.
77. Peroutka, S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol. Interv., 2005, 5, 304-11.
78. Ferrari, M.D.; Färkkilä, M.; Reuter, U.; Pilgrim, A.; Davis, C.; Krauss, M.; Diener, H.C. European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan a randomised proof-of-concept trial. Cephalalgia, 2010, 30, 1170-8.
79. Nelson, D.L.; Phebus, L.A.; Johnson, K.W.; Wainscott, D.B.; Cohen, M.L.; Calligaro, D.O.; Xu, Y.C. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia, 2010, 30, 1159-69.
80. Monteith, T.S.; Goadsby, P.J. Acute migraine therapy: new drugs and new approaches. Curr. Treat Options Neurol., 2011, 13, 1-14.
81. Bellavance, A.J.; Meloche, J.P. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache, 1990, 30, 710-5.
82. Silberstein, S.D. Methysergide. Cephalalgia, 1998, 18, 421-35.
83. Koehler, P.J.; Tfelt-Hansen, P.C. History of methysergide in migraine. Cephalalgia, 2008, 28, 1126-35.
84. Bahra, A.; Walsh, M.; Menon, S.; Goadsby, P.J. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache, 2003, 43, 179-90.
85. Radat, F.; Creac'h, C.; Guegan-Massardier, E.; Mick, G.; Guy, N.; Fabre, N.; Giraud, P.; Nachit-Ouinekh, F.; Lantéri-Minet, M. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache, 2008, 48, 1026-36.
86. Yaksh, T.; Young, C.; Rudy, T. systematic examination of the rat brain sites sensitive to direct application of morphin: Observation of differential effects with the periaqueductal gray. Brain Res., 1976, 114, 83-103.
87. Basbaum, A.; Field, H. The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: further studies on the anatomy of pain modulation. J. Comp. Neurol., 1979, 187, 513-532.
88. Reichling, D. B.; Kwait, G. C.; Basbaum, A. I. Anatomy and pharmachology of the periaqueductal gray contribution to antinociceptive controls. Prog. Brain Res., 1988, 77, 31-46.
89. Reichling, D.; Basbaum, A. Contribution of brainstem GABAergic circuitry to descending antinociceptive controls I. GABAimmunoreactive projection neurons in the periaqueductal gray and nucleus raphe magnus. J. Comp. Neurol., 1990, 302, 370-377.
90. Moskowitz, M.A.; Brezina, L. R.; Kuo, C. Dynorphin B-containing perivascular axons and sensory neurotransmitter mechanisms in brain blood vessels. Cephalalgia, 1986, 6, 81-86.
91. Martin-Schild, S.; Gerall, A. A.; Kastin, A. J.; Zadina, J. E. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides, 1998, 19, 1783-1789.
92. Yaksh, T. L.; Michener, S. R.; Bailey, J. E.; Harty, G. J.; Lucas, D. L.; Nelson, D. K.; Roddy, D. R.; Go, V. L. Survey of distribution of substance P, vasoactive intestinal peptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of the cat, dog, sloth and monkey. Peptides, 1988, 9, 357-372.
93. Zhang, R.X.; Mi, Z. P.; Qiao, J.T. Changes of spinal substance P, calcitonin gene-related peptide, somatostatin, Met-enkephalin and neurotensin in rats in response to formalin-induced pain. Regul. Pept., 1994, 51, 25-32.
94. Saria, A.; Hauser, K. F.; Traurig, H. H.; Turbek, C. S.; Hersh, L.; Gerard, C. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice. Neurosci. Lett., 1997, 234, 27-30.
95. Yaksh, T.L.; Elde, R. Factors governing release of methionine enkephalin-like immunoreactivity from mesencephalin and spinal cord of the cat in vivo. J. Neurophysiol., 1981, 46, 1056-1075.
96. Samsam, M.; Coveñas, R.; Ahangari, M.; Yajeya, J.; Narváez, J.A.; Montes, C.; Gonzßález-Barón, S. Implication of the neuropeptides methionine enkephalin, neurotensin and somatostatin of the caudal trigeminal nucleus in the experimental migraine. Rev. Neurol., 2002, 34, 724-729.
97. Mosnaim, A.D.; Wolf, M.E.; Chevesich, J.; Callaghan, O.H.; Diamond, S. Plasma methionine enkephalin levels. A biological marker for migraine? Headache, 1985, 25, 259-261.
98. Mosnaim, A.D.; Chevesich, J.; Wolf, M.E.; Freitag, F.G.; Diamond, S. Plasma methionine enkephalin. Increased levels during a migraine episode. Headache, 1986, 26, 278-281.
99. Edvinsson, L. Neuronal signal substances as biomarkers of migraine. Headache, 2006, 46, 1088-1094.
100. Williamson, D.J.; Shepheard, S.L.; Cook, D.A.; Hargreaves, R.J.; Hill, R.G.; Cumberbatch, M.J. Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br. J. Pharmacol., 2001, 133, 807-814.
101. Bigal, M.E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W.F.; Lipton, R.B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache, 2008, 48, 1157-68.
102. Katsarava, Z.; Limmroth, V.; Finke, M.; Diener, H.C.; Fritsche, G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology, 2003, 60, 1682-3.
103. Biondi, D.M. Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr. Pain Headache Rep., 2003, 7, 67-75.
104. Wasay, M.; Zaki, K.S.; Khan, S.U.; Rehmani, R. Narcotic analgesics for acute migraine in the emergency room: are we meeting Headache Societies' guidelines? J. Headache Pain, 2006, 7, 413-415.
105. Amara, S.G.; Jonas, V.; Rosenfeld, M.G.; Ong, E.S.; Evans, R.M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 1982, 298, 240-4.
106. Brain, S.D.; Williams, T.J.; Tippins, J.R.; Morris, H.R.; MacIntyre, I. Calcitonin gene-related peptide is a potent vasodilator. Nature, 1985, 313, 54-6.
107. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; and Narváez, J.A. Role of neuropeptides in migraine; where do they stand in the latest expert recommendations in migraine treatment? Drug Develp. Res., 2007, 68, 298-314.
108. Arulmani, U.; Gupta, S.; Massen Van Den Brink, A.; Centurion, D.; Villalon, C.M.; Saxena, P.R. Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 2006, 26, 642-659.
109. Knyihár-Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Vécsei, L. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci. Lett., 1995, 184, 189-192.
110. Messlinger, K.; Hanesch, U.; Kurosawa, M.; Pawlak, M.; Schmidt, R.F. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can. J. Physiol. Pharmacol., 1995, 73, 1020-1024.
111. Nichols, FI.; Mawad, M.; Mohr, J.; Stein, B.; Hilal, S.; Michelsen, J. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke, 1990, 21, 555-559.
112. Olesen, J.; Friberg, L.; Olesen, T.; Iversen, H.K.; Lassen, N.A.; Andersen, A.R.; Karle, A. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol., 1990, 28, 791-798.
113. May, A.; Buchel, C.; Turner, R.; Goadsby, P.J. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J. Cereb. Blood Flow Metab., 2001, 21, 1171-
114. Knyihár Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Buzás, P.; Vécsei, L. Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion. Exp. Brain Res., 1998, 118, 111-114.
115. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narvaéz, J.A.; Tramu, G. Alterations in neurokinin A, substance P and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion. Neurosci. Lett., 1999, 261, 179-182.
116. Samsam, M.; Knyihár-Csillik, E.; Sáry, G.; Vécsei, L. Effects of lesions of the Gasserian ganglion on the CGRP immunoreactivity of the caudal trigeminal nucleus. Neurobiology, 1996, 4, 169.
117. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J.; Narvaéz, J.A.; Tramu, G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain, 2000, 84, 389-395.
118. Samsam, M.; Coveñas, R.; Csillik, B.; Ahangari, R.; Yajeya, J.; Riquelme, R.; Narvaéz, J.A.; Tramu, G. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion: a possible neurophysiological and neuroanatomical link to generalized head pain. J. Chem. Neuroanat., 2001, 21, 161-169.
119. Knyihár Csillik, E.; Tajti, J.; Samsam, M.; Sáry, G.; Buzás, P.; Vécsei, L. Effect of a serotonin agonist (Sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J. Neurosci. Res., 1997, 48, 449-464.
120. Tfelt-Hansen, P.; Le, H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J. Headache Pain., 2009, 10, 137-43.
121. Olesen, J.; Diener, H.C.; Husstedt, I.W. Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L.M. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med., 2004, 350, 1104-1110.
122. Edvinsson, L.; Alm. R.; Shaw, D.; Rutledge, R.Z.; Koblan, K.S.; Longmore, J.; Kane, S.A. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur. J. Pharmacol., 2002, 434, 49-53.
123. Jansen-Olesen, I.; Jorgensen, L.; Engel, U.; Edvinsson, L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur. J. Pharmacol., 2003, 481, 207-216.
124. Wu, D.; Eberlein, W.; Rudolf, K.; Engel, W.; Hallermayer, G.; Doods, H. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur. J. Pharmacol., 2000, 400, 313-319.
125. Jansen-Olesen, I.; Kaarill, L.; Edvinsson, L. Characterization of CGRP(1) receptors in the guinea pig basilar artery. Eur. J. Pharmacol., 2001, 414, 249-258.
126. Wu, D.; Doods, H.; Arndt, K.; Schindler, M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem. Soc. Trans., 2002, 30, 468-473.
127. Gupta, S.; Akerman, S.; van den Maagdenberg, A.M.; Saxena, P.R.; Goadsby, P.J.; van den Brink, A.M. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia, 2006, 26, 1294-303.
128. Petersen, K.A.; Birk, S.; Lassen, L.H.; Kruuse, C.; Jonassen, O.; Lesko, L.; Olesen, J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia, 2005, 25, 139-47.
129. Tröltzsch, M.; Denekas, T.; Messlinger, K. The calcitonin generelated peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur. J. Pharmacol., 2007, 562, 103-110.
130. Gupta, S.; Mehrotra, S.; Villalon, C.M.; Garrelds, I.M.; de Vries, R.; van Kats, J.P.; Sharma, H.S.; Saxena, P.R.; Maassen van den brink, A. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur. J. Pharmacol., 2006, 530, 107-116.
131. Hasbak, P.; Saetrum Opgaard, O.; Eskesen, K.; Schifter, S.; Arendrup, H.; Longmore, J.; Edvinsson, L. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J. Pharmacol. Exp. Ther., 2003, 304, 326-333.
132. Sixt, M.L.; Messlinger, K.; Fischer, M.J. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain, 2009, 132, 3134-41.
133. Ho, TW.; Mannix, L.K.; Fan, X.; Assaid, C.; Furtek, C.; Jones, C.J.; Lines, C.R.; Rapoport, A.M. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 2008, 70, 1304-12.
134. Connor, K.M.; Shapiro, R.E.; Diener, H.C.; Lucas, S.; Kost, J.; Fan, X.; Fei, K.; Assaid, C.; Lines, C.; Ho, T.W. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology, 2009, 73, 970-7.
135. Iovino, M.; Feifel, U.; Yong, C.L.; Wolters, J.M.; Wallenstein, G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia, 2004, 24, 645-56.
136. Ho, T.W.; Ferrari, M.D.; Dodick, D.W.; Galet, V.; Kost, J.; Fan, X.; Leibensperger, H.; Froman, S.; Assaid, C.; Lines, C.; Koppen, H.; Winner, P.K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet, 2008, 372, 2115-23.
137. Summ, O. Charbit, A.R., Andreou, A.P., Goadsby, P.J. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain, 2010, 133(9), 2540-8.
138. Tepper, S.J.; Cleves, C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. Investig. Drugs, 2009, 10, 711-20.
139. Tfelt-Hansen, P.; Olesen, J. Possible site of action of CGRP antagonists in migraine. Cephalalgia, 2011, 31, 748-50.
140. Benemei, S.; Nicoletti, P.; Capone, J.A.; Geppetti, P. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci., 2007, 28, Suppl 2, S89-93.
141. Olesen, J.; Thomsen, L.L.; Lassen, L.H.; Olesen, I.J. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia, 1995, 15, 94-100.
142. Thomsen, L.L.; Olesen, J. Nitric oxide in primary headaches. Curr. Opin. Neurol., 2001, 14, 315-321.
143. Lazarov, N.E. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog. Neurobiol., 2002, 66, 19-59.
144. Joubert, J.; Malan, S.F. Novel nitric oxide synthase inhibitors: a patent review. Expert Opin Ther. Pat. 2011, 21, 537-60.
145. Ramachandran, R.; Ploug, K.B.; Hay-Schmidt, A.; Olesen, J.; Jansen-Olesen, I.; Gupta, S. Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. Neurosci. Lett., 2010, 484, 192-6.
146. Olesen, J.; Thomsen, L.L.; Iversen, H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci., 1994, 15, 149-53.
147. Iversen, H.K. Human migraine models. Cephalalgia, 2001, 21, 781-785.
148. Lassen, L.H.; Haderslev, P.A.; Jacobsen, V.B.; Iversen, H.K.; Sperling, B.; Olesen, J. CGRP may play a causative role in migraine. Cephalalgia, 2002, 22, 54-61.
149. Messlinger, K.; Suzuki, A.; Pawlak, M.; Zehnter, A.; Schmidt, R.F. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br. J. Pharmacol., 2000, 129, 1397-1404.
150. Strecker, T.; Dux, M.; Messlinger, K. Increase in meningeal blood flow by nitric oxide--interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia, 2002, 22, 233-241.
151. Akerman, S.; Williamson, D.J.; Kaube, H.; Goadsby, P.J. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br. J. Pharmacol., 2002, 137, 62-68.
152. Kruuse, C.; Iversen, H.K.; Jansen-Olesen, I.; Edvinsson, L.; Olesen, J. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia, 2009, DOI:10.1111/j.1468-2982.2009.01963.x.
153. De Alba, J.; Clayton, N.M.; Collins, S.D.; Colthup, P.; Chessell, I.; Knowles, R.G. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain, 2006, 120, 170-81.
154. Sprenger, T.; Goadsby, P.J. Migraine pathogenesis and state of pharmacological treatment options. BMC Med., 2009, 7, 71.
155. Birk, S.; Kruuse, C.; Petersen, K.A.; Tfelt-Hansen, P.; Olesen, J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia., 2006, 26, 1304-9.
156. Bellamy, J.; Bowen, E.J.; Russo, A.F.; Durham, P.L. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci., 2006, 23, 2057-2066.
157. Vause, C.V.; Durham, P.L. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogenactivated protein kinase pathways. J. Neurochem., 2009, 110, 811-21.
158. Hoskin, K.L.; Bulmer, D.C.; Goadsby, P.J. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci. Lett., 1999, 266, 173-6.
159. Olesen, J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol. Ther., 2008, 120, 157-171.
160. Yaksh, T.L. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol. Sci., 1999, 20, 329-337.
161. De Felice, M.; Ossipov, M.H.; Wang, R.; Dussor, G.; Lai, J.; Meng, I.D.; Chichorro, J.; Andrews, J.S.; Rakhit, S.; Maddaford, S.; Dodick, D.; Porreca, F. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain., 2010,133(Pt 8), 2475-88.
162. Kai-Kai, M.A.; Howe, R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intraspinal neurons and fibres in the dorsal horn of the rat. Histochem. J., 1991, 23, 171-9.
163. Clayton, J.S.; Gaskin, P.J.; Beattie, D.T. Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig. Brain Res., 1997, 775, 74-80.
164. Bereiter, D.A.; Bereiter, D.F.; Tonnessen, B.H.; Maclean, D.B. Selective blockade of substance P or neurokinin A receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat. Neuroscience, 1998, 83, 525-34.
165. Chasman, D.I.; Schürks, M.; Anttila, V.; de Vries, B.; Schminke, U.; Launer, L.J.; Terwindt, G.M.; van den Maagdenberg, A.M.; Fendrich, K.; Völzke, H.; Ernst, F.; Griffiths, L.R.; Buring, J.E.; Kallela, M.; Freilinger, T.; Kubisch, C.; Ridker, P.M.; Palotie, A.; Ferrari, M.D.; Hoffmann, W.; Zee, R.Y.; Kurth, T. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat. Genet., 2011, 43, 695-8.
166. Tottene, A.; Urbani, A.; Pietrobon, D. Role of different voltagegated Ca2+ channels in cortical spreading depression: specific requirement of P/Q-type Ca2+ channels. Channels (Austin). 2011, 5, 110-4.
167. Pietrobon, D. Biological science of headache channels. Handb. Clin. Neurol., 2010, 97, 73-83.
168. Holland, P.R.; Akerman, S.; Goadsby, P.J. Cortical spreading depression-associated cerebral blood flow changes induced by mechanical stimulation are modulated by AMPA and GABA receptors. Cephalalgia, 2010, 30, 519-27.
169. Basbaum, A. I.; Woolf, C.J. Pain. Curr. Biol., 1999, 9, R429-R431.
170. Ramadan, N.M. The link between glutamate and migraine. CNS Spectr., 2003, 8, 446-449.
171. Mitsikostas, D.D.; Sanchez del Rio, M.; Waeber, C.; Moskowitz, M.A.; Cutrer, F.M. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain, 1998, 76, 239-248.
172. Weiss, B.; Alt, A.; Ogden, A.M.; Gates, M.; Dieckman, D.K.; Clemens-Smith, A.; Ho, K.H.; Jarvie, K.; Rizkalla, G.; Wright, R.A.; Calligaro, D.O.; Schoepp, D.; Mattiuz, E.L.; Stratford, R.E.; Johnson, B.; Salhoff, C.; Katofiasc, M.; Phebus, L.A.; Schenck, K.; Cohen, M.; Filla, S.A.; Ornstein, P.L.; Johnson, K.W.; Bleakman, D. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J. Pharmacol. Exp. Ther., 2006, 318, 772-81.
173. Blumenfeld, A.; Silberstein, S.D.; Dodick, D.W.; Aurora, S.K.; Turkel, C.C.; Binder, W.J. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache, 2010, 50, 1406-18.
174. Mauskop, A. Botulinum neurotoxin in the treatment of headache disorders. Handb. Clin. Neurol., 2010, 97, 217-32.
175. Párdutz, A.; Fejes, A.; Bohár, Z.; Tar, L.; Toldi, J.; Vécsei, L. Kynurenines and headache. J. Neural. Transm., 2011 Jun 4. [Epub ahead of print].
176. Cutrer, F.M. Antiepileptic drugs: how they work in headache. Headache, 2001, 41 Suppl 1, S3-10.
177. Löscher, W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol., 1999, 58, 31-59.
178. Perucca, E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs, 2002, 16, 695-714.
179. Brodie, M.J. Antiepileptic drug therapy the story so far. Seizure, 2010, 19, 650-5.
180. Kaniecki, R.G. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch. Neurol., 1997, 54, 1141-5.
181. Klapper, J. Divalproex sodium in migraine prophylaxis: a dosecontrolled study. Cephalalgia, 1997, 17, 103-8.
182. Young, W.B.; Hopkins, M.M.; Shechter, A.L.; Silberstein, S.D. Topiramate: a case series study in migraine prophylaxis. Cephalalgia, 2002, 22, 659-63.
183. Mathew, N.T.; Kailasam, J.; Meadors, L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache, 2002, 42, 796-803.
184. Mei, D.; Capuano, A.; Vollono, C.; Evangelista, M.; Ferraro, D.; Tonali, P.; Di Trapani, G. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol. Sci., 2004, 25, 245-50.
185. Silberstein, S.D. Topiramate in migraine prevention. Headache, 2005, 45 Suppl 1, S57-65.
186. Silberstein, S.D.; Lipton, R.B.; Dodick, D.W.; Freitag, F.G.; Ramadan, N.; Mathew, N.; Brandes, J.L.; Bigal, M.; Saper, J.; Ascher, S.; Jordan, D.M.; Greenberg, S.J.; Hulihan, J. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache, 2007, 47, 170-80.
187. Diener, H.C.; Bussone, G.; Van Oene, J.C.; Lahaye, M.; Schwalen, S.; Goadsby, P.J. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia, 2007, 27, 814-23.
188. Akerman, S.; Goadsby, P.J. Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br. J. Pharmacol., 2005, 146, 7-14.
189. Durham, P.L.; Niemann, C.; Cady, R. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache, 2006, 46, 1291-5.
190. Akerman, S.; Goadsby, P.J. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport, 2005, 16, 1383-7.
191. Silberstein, S.; Saper, J.; Berenson, F.; Somogyi, M.; McCague, K.; D'Souza, J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology, 2008, 70, 548-55.
192. Kennedy, G.M.; Lhatoo, S.D. CNS adverse events associated with antiepileptic drugs. CNS Drugs, 2008, 22, 739-60.
193. Min, J.H.; Kwon, H.M.; Nam, H. The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine. J. Neurol. Sci., 2011, 305, 136-8.
194. Ferrari, A.; Spaccapelo, L.; Pinetti, D.; Tacchi, R.; Bertolini, A. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia, 2009, 29, 423-9.
195. Casucci, G, Villani, V.; Frediani, F. Central mechanism of action of antimigraine prophylactic drugs. Neurol. Sci., 2008, 29 Suppl 1:S123-6.
196. Richter, F.; Mikulik, O.; Ebersberger, A.; Schaible, H.G. Noradrenergic agonists and antagonists influence migration of cortical spreading depression in rat-a possible mechanism of migraine prophylaxis and prevention of postischemic neuronal damage. J. Cereb. Blood Flow Metab., 2005, 25, 1225-35.
197. Shields, K.G.; Goadsby, P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain, 2005, 128, 86-97.
198. Louis, P., Spierings, E.L. Comparison of flunarizine (Sibelium) and pizotifen (Sandomigran) in migraine treatment: a double-blind study. Cephalalgia, 1982, 2, 197-203.
199. Wauquier, A.; Ashton, D.; Marrannes, R. The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia, 1985, 5 Suppl 2, 119-23.
200. Fanciullacci, M.; Pietrini, U.; Nicolodi, M.; Sicuteri, F. Nonvascular action of calcium blockers in migraine: pupillopharmacological study. Funct. Neurol., 1986, 1, 533-7.
201. Leone, M.; Grazzi, L.; La Mantia, L.; Bussone, G. Flunarizine in migraine: a minireview. Headache, 1991, 31, 388-91.
202. Bonuccelli, U.; Piccini, P.; Paoletti, A.M.; Nuti, A.; Colzi, A.; Melis, G.B.; Muratorio, A. Flunarizine increases PRL secretion in normal and in migraineous women. J. Neural. Transm., 1988, 74, 43-53.
203. Casucci, G.; Di Costanzo, A.; Riva, R.; Albani, F.; Bonavita, V.; Tedeschi, G. Central action of cinnarizine and flunarizine: a saccadic eye movement study. Clin. Neuropharmacol., 1994, 17, 417-22.
204. Ye, Q.; Yan, L.Y.; Xue, L.J.; Wang, Q.; Zhou, Z.K.; Xiao, H.; Wan, Q. Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine. Neurosci. Lett., 2011, 487, 394-9.
205. Benarroch, E.E. Pain-autonomic interactions. Neurol. Sci., 2006, 27, Suppl 2, S130-133.
206. Fields, H.L. Pain modulation: expectation, opioid analgesia and virtual pain. Prog. Brain Res., 2000, 122, 245-253.
207. Samsam, M.; Coveñas, R.; Ahangari, R.; Yajeya, J. In: Neuroanatomy Research Advances; Editors: CE Flynn, and BR Callaghan, Ed; Nova Science Publishers: New York, 2009, pp. 1-58.
208. Millan, M.J. The induction of pain: an integrative review. Prog. Neurobiol., 1999, 57, 1-164.
209. Millan, M.J. Descending control of pain. Prog. Neurobiol., 2002, 66, 355-474.
210. Vaughan, D.; Speed, J.; Medve, R.; Andrews, J.S. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clin. Ther., 2010, 32, 146-60.
211. Silberstein, S.D. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2000, 55, 754-62.
212. Maassen, V. Den, B., A.; Saxena, P.R. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache, 2004, 44, Suppl 1:S13-9.
213. Demaagd, G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T, 2008, 33, 404-16.
214. Demaagd, G. The pharmacological management of migraine, part 2: preventative therapy. P T, 2008, 33, 480-7.
215. Panconesi, A.; Anselmi, B.; Curradi, C.; Perfetto, F.; Piluso, A.; Franchi, G. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache, 1994, 34, 194-7.
216. Galletti, F.; Cupini, L.M.; Corbelli, I.; Calabresi, P.; Sarchielli, P. Pathophysiological basis of migraine prophylaxis. Prog. Neurobiol., 2009, 89, 176-92.
217. Salvatore, C.A.; Hershey, J.C.; Corcoran, H.A.; Fay, J.F.; Johnston, V.K.; Moore, E.L.; Mosser, S.D.; Burgey, C.S.; Paone, D.V.; Shaw, A.W.; Graham, S.L.; Vacca, J.P.; Williams, T.M.; Koblan, K.S.; Kane, S.A. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl) azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther., 2008, 324, 416-21.
218. Doods, H.; Hallermayer, G.; Wu, D.; Entzeroth, M.; Rudolf, K.; Engel, W.; Eberlein, W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol., 2000, 129, 420-3.
219. Di Paola, R.; Mazzon, E.; Patel NS. Genovese, T.; Muià, C.; Thiemermann, C.; De Sarro A.; Cuzzocrea, S.; Beneficial effects of GW274150 treatment on the development of experimental colitis induced by dinitrobenzene sulfonic acid. Eur. J. Pharmacol., 2005, 507, 281-9.
220. Weiss, B.; Alt, A.; Ogden, A.M.; Gates, M.; Dieckman, D.K.; Clemens-Smith, A.; Ho, K.H.; Jarvie, K.; Rizkalla, G.; Wright, R.A.; Calligaro, D.O.; Schoepp, D.; Mattiuz, E.L.; Stratford, R.E.; Johnson, B.; Salhoff, C.; Katofiasc, M.; Phebus, L.A.; Schenck, K., Cohen, M.; Filla, S.A.; Ornstein, P.L.; Johnson, K.W.; Bleakman, D. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in Vitro and in Vivo. J. Pharmacol. Exp. Ther., 2006, 318, 772-781.
221. Diener. H.C.; Barbanti, P.; Dahlof, C.; Reuter, U.; Habeck, J.; Podhorna. J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011, 31, 573-84.